ACE and hydrops fetalis: The combination of angiotensin-converting enzyme inhibitors (ACE-I) or an angiotensin receptor–neprilysin inhibitor (ARNI), a beta-blocker, and a mineralocorticoid receptor antagonist (MRA) is established as the cornerstone treatment for these HF-subtype patients (except in those cases when these drugs are contraindicated or not tolerated) [4,5,6].